This thing has gotten a lot of press and most of the stories I've read have not mentioned that this one form of leukemia only has 4,300 cases a year in the U.S. I did find one story which suggests this drug may be applicable to other forms of leukemia. The following is an excerpt from the BBC article:
However, an authority on leukaemia, Professor John Goldman, who will be heading a larger-scale trial of the drug at the Hammersmith Hospital in London, said: "Usually these things are blown out of proportion, but this is real.
"It looks very promising for people with chronic myeloid leukaemia, and might also be useful for people with other forms of leukaemia."
On the other hand, according to the Novartis website, the ADRs are actually traded on the pink sheets. Also, it mentions that 20 ADRs are equal to 1 registered share. Does that mean that each registered share is currently valued at about $1600?
I know this will see some action on Monday, but I wonder how much. The fact that it trades on the pink sheets and is relatively expensive should put a damper on things. |
